Hainan Puli Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") announces that the trading of its stock and convertible bonds (hereinafter referred to as "convertible bonds" or "Puli convertible bonds") will enter a delisting adjustment period starting from April 28, 2025, lasting for fifteen trading days, with the expected last trading day on May 21, 2025. The Company's stock and convertible bonds will be delisted on the trading day following the end of the adjustment period.
-
During the delisting adjustment period, the Company will not plan or implement any major asset restructuring. For relevant trading rules and investor suitability arrangements during the delisting adjustment period for convertible bonds, investors are advised to refer to the "Notice on Trading Arrangements for Convertible Bonds During the Delisting Adjustment Period" (Shenzhen Stock Exchange [2023] No. 492) and the "Notice on Improving Investor Suitability Management Related Matters for Convertible Bonds (2025 Revision)" (Shenzhen Stock Exchange [2025] No. 223).
-
Investors, securities companies, and other market participants are advised to settle stock pledge repurchase, agreed repurchase, margin financing, transfer, and Shenzhen Stock Connect businesses before the stock is delisted.
-
For judicial freeze businesses that will expire between the stock delisting and the completion of the initial registration in the delisting sector, it is recommended that the competent authorities handle the renewal procedures in advance through the original enforcement channels before the stock is delisted.
-
The Company's stock is classified as a special security under the Shenzhen Stock Connect, and investors in the Shenzhen Stock Connect can only sell but not buy. After the stock enters the delisting sector, investors may not be able to transfer the stock, and investors are reminded to pay attention to investment risks.
-
Since February 9, 2025, the Company's convertible bonds have entered the repurchase period (the last two interest-bearing years). During the repurchase period, if the closing price of the Company's stock is below 70% of the current conversion price for any consecutive thirty trading days, the Company may face early repayment requests for part of the convertible bonds' principal and interest, which may lead to risks of not being able to repay in full.
The Shenzhen Stock Exchange (hereinafter referred to as "SZSE") issued a decision on April 18, 2025, regarding the termination of the listing of Hainan Puli Pharmaceutical Co., Ltd.'s stock and convertible bonds (Shenzhen Stock Exchange [2025] No. 357). The SZSE has decided to terminate the listing of the Company's stock and convertible bonds. According to the relevant provisions of the "Shenzhen Stock Exchange GEM Stock Listing Rules" and the "Notice on Trading Arrangements for Convertible Bonds During the Delisting Adjustment Period" (Shenzhen Stock Exchange [2023] No. 492), the Company's stock and convertible bonds will enter the delisting adjustment period starting from April 28, 2025. The relevant arrangements for the trading of the Company's stock and convertible bonds during the delisting adjustment period are announced as follows: